Extrafine beclometasone/LABD formulations did not increase pneumonia risk versus LABD

Dave  Singh; David Price; William  Henley; José Eduardo  Delfini Cançado; Leonardo M Fabbri; Huib AM  Kerstjens; Alberto Papi; Nicolas Roche; Elif  Şen; Claus F Vogelmeier; Elena  Nudo; Victoria Carter; Derek Skinner; Rebecca  Vella; Joan B Soriano; Maxim  Kots; George  Georges

Extrafine beclometasone/LABD formulations did not increase pneumonia risk versus LABD

Dave Singh
, David Price
, William Henley
, José Eduardo Delfini Cançado
, Leonardo M Fabbri
, Huib AM Kerstjens
, Alberto Papi
, Nicolas Roche
, Elif Şen
, Claus F Vogelmeier
, Elena Nudo
, Victoria Carter
, Derek Skinner
, Rebecca Vella
, Joan B Soriano
, Maxim Kots
, George Georges

University of Manchester
Observational and Pragmatic Research Institute Singapore
Santa Casa de São Paulo Medical School
University of Groningen
Université Paris Descartes
Hôpital Hôtel-Dieu AP-HP
Université Paris 5
Ankara University
Universitätsklinikum Giessen und Marburg, Standort Marburg
Global Medical Affairs, Chiesi Farmaceutici
Optimum Patient Care Ltd, Cambridge
Universidad Autónoma de Madrid
Global Clinical Development, Chiesi Farmaceutici

Research output: Contribution to conference › Abstract › peer-review

3 Downloads (Pure)

Abstract

Combined ICS and long-acting bronchodilators (LABD) more effectively reduce COPD exacerbations than LABD therapy alone. Corticosteroid-related adverse effects, including pneumonia, limit ICS use. Previous data suggest this risk is lower for extrafine beclometasone (ef-BDP). The objective was to compare pneumonia risk among new users of fixed dose ICS/LABD formulations containing ef-BDP, versus patients initiating LABD without any ICS.

Original language	English
Publication status	Published - 26 Mar 2024
Event	TSANZSRS 2024: The Thoracic Society of Australia and New Zealand and the Australian and New Zealand Society of Respiratory Science - Gold Coast Convention and Exhibition Centre, Gold Coast, Australia Duration: 23 Mar 2024 → 26 Mar 2024 https://tsanzsrsasm.com/

Conference

Conference	TSANZSRS 2024
Abbreviated title	TSANZSRS
Country/Territory	Australia
City	Gold Coast
Period	23/03/24 → 26/03/24
Internet address	https://tsanzsrsasm.com/

Access to Document

Singh_etal_Extrafine_beclometasone_LABD_AAM
This accepted author manuscript has been made open access under the University of Aberdeen Rights Retention Policy. It is available under a Creative Commons Attribution license https://creativecommons.org/licenses/by/4.0/ Final published version available at https://doi.org/[doi]
Accepted author manuscript, 151 KBLicence: CC BY

Cite this

Singh, D., Price, D., Henley, W., Delfini Cançado, J. E., Fabbri, L. M., Kerstjens, H. AM., Papi, A., Roche, N., Şen, E., Vogelmeier, C. F., Nudo, E., Carter, V., Skinner, D., Vella, R., Soriano, J. B., Kots, M., & Georges, G. (2024). Extrafine beclometasone/LABD formulations did not increase pneumonia risk versus LABD. Abstract from TSANZSRS 2024, Gold Coast, Australia.

@conference{d0f13a85a7e84ba8b63d85498d2c2812,

title = "Extrafine beclometasone/LABD formulations did not increase pneumonia risk versus LABD",

abstract = "Combined ICS and long-acting bronchodilators (LABD) more effectively reduce COPD exacerbations than LABD therapy alone. Corticosteroid-related adverse effects, including pneumonia, limit ICS use. Previous data suggest this risk is lower for extrafine beclometasone (ef-BDP). The objective was to compare pneumonia risk among new users of fixed dose ICS/LABD formulations containing ef-BDP, versus patients initiating LABD without any ICS.",

author = "Dave Singh and David Price and William Henley and \{Delfini Can{\c c}ado\}, \{Jos{\'e} Eduardo\} and Fabbri, \{Leonardo M\} and Kerstjens, \{Huib AM\} and Alberto Papi and Nicolas Roche and Elif {\c S}en and Vogelmeier, \{Claus F\} and Elena Nudo and Victoria Carter and Derek Skinner and Rebecca Vella and Soriano, \{Joan B\} and Maxim Kots and George Georges",

year = "2024",

month = mar,

day = "26",

language = "English",

note = "TSANZSRS 2024 : The Thoracic Society of Australia and New Zealand and the Australian and New Zealand Society of Respiratory Science , TSANZSRS ; Conference date: 23-03-2024 Through 26-03-2024",

url = "https://tsanzsrsasm.com/",

}

TY - CONF

T1 - Extrafine beclometasone/LABD formulations did not increase pneumonia risk versus LABD

AU - Singh, Dave

AU - Price, David

AU - Henley, William

AU - Delfini Cançado, José Eduardo

AU - Fabbri, Leonardo M

AU - Kerstjens, Huib AM

AU - Papi, Alberto

AU - Roche, Nicolas

AU - Şen, Elif

AU - Vogelmeier, Claus F

AU - Nudo, Elena

AU - Carter, Victoria

AU - Skinner, Derek

AU - Vella, Rebecca

AU - Soriano, Joan B

AU - Kots, Maxim

AU - Georges, George

PY - 2024/3/26

Y1 - 2024/3/26

N2 - Combined ICS and long-acting bronchodilators (LABD) more effectively reduce COPD exacerbations than LABD therapy alone. Corticosteroid-related adverse effects, including pneumonia, limit ICS use. Previous data suggest this risk is lower for extrafine beclometasone (ef-BDP). The objective was to compare pneumonia risk among new users of fixed dose ICS/LABD formulations containing ef-BDP, versus patients initiating LABD without any ICS.

AB - Combined ICS and long-acting bronchodilators (LABD) more effectively reduce COPD exacerbations than LABD therapy alone. Corticosteroid-related adverse effects, including pneumonia, limit ICS use. Previous data suggest this risk is lower for extrafine beclometasone (ef-BDP). The objective was to compare pneumonia risk among new users of fixed dose ICS/LABD formulations containing ef-BDP, versus patients initiating LABD without any ICS.

M3 - Abstract

T2 - TSANZSRS 2024

Y2 - 23 March 2024 through 26 March 2024

ER -

Extrafine beclometasone/LABD formulations did not increase pneumonia risk versus LABD

Abstract

Conference

Access to Document

Fingerprint

Cite this